Yoko Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoko Suzuki has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Gusty Rizky Teguh Ryanto
Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Higashinada, Japan
2 shared publications - Noriaki Emoto
Kobe University Graduate School of Medicine
2 shared publications - Dyah Samti Mayasari
Faculty of Medicine Public Health and Nursing Faculty of Medicine Gadjah Mada University Daerah Istimewa Yogyakarta -Indonesia Universitas Islam Indonesia
1 shared publication - Hiromasa Otake
Kobe University Graduate School of Medicine
1 shared publication - Hiroshi Kitagawa
Kobe Pharmaceutical University
1 shared publication - Imam Manggalya Adhikara
Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 May 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (5) , e323681
Activin A–Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH
BACKGROUND: Pulmonary arterial hypertension remains a life-threatening disease despite advances in vasodilator therapy. Vascular remodeling, partly driven by pulmonary artery endothelial cell dysfunction, is accompanied by vasoactive mediators imbalance such as ET-1 (endothelin-1). Although endothelin receptor antagonists alleviate vasoconstriction, they incompletely address the remodeling process. We previously reported how endothelial-derived activin A promotes vascular remodeling, leading to the clinical development of the activin signaling inhibitor sotatercept, which improves outcomes when added to endothelin receptor antagonists. As both activin A and ET-1 originate from endothelial cells and promote remodeling, we investigated whether activin A regulates ET-1 production and activity in pulmonary arterial hypertension. METHODS: In vitro, we used pulmonary artery endothelial cell models of activin A overabundance alone or cocultured with pulmonary artery smooth muscle cells. Cells were treated with either the activin A inhibitor FST (follistatin), the endothelin receptor antagonist bosentan, the FST/bosentan combination, or vehicle for analysis. In vivo, we exposed wild-type or endothelial-specific INHBA (inhibin β-A)-overexpressing mice (VEcadherin-INHBA-Transgenic/VEcad-INHBA-Tg) to chronic hypoxia pulmonary hypertension model, with the addition of FST, bosentan, FST and bosentan, or vehicle treatments after the first week of hypoxia exposure. RESULTS: Activin A upregulated ET-1 expression via canonical SMAD2/3 (small mother against decapentaplegic family member 2/3) signaling in pulmonary artery endothelial cells. This induction, as well as ET-1–driven downstream effects—including reduced eNOS (endothelial NO synthase), pulmonary artery smooth muscle cell phenotypic switching, oxidative stress, and endothelial-to-mesenchymal transition—was reversed by FST alone or in combination with bosentan. In vivo, FST-based therapy achieved greater hemodynamic, right ventricular remodeling, and vascular structural normalization in wild-type and VEcad-INHBA-Tg mice than bosentan alone, accompanied by stronger ET-1 suppression. CONCLUSIONS: We identified ET-1 as a downstream effector of activin A in pulmonary arterial hypertension development, supporting activin A blockade as a strategy to inhibit ET-1–mediated vasoconstriction and remodeling. This mechanistic link provides a rationale for the rapid clinical benefits observed with sotatercept and suggests its potential role earlier in the pulmonary arterial hypertension treatment paradigm.
- 1 May 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (5) , e323681
Top Cited PapersOpen AccessActivin A–Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH
BACKGROUND: Pulmonary arterial hypertension remains a life-threatening disease despite advances in vasodilator therapy. Vascular remodeling, partly driven by pulmonary artery endothelial cell dysfunction, is accompanied by vasoactive mediators imbalance such as ET-1 (endothelin-1). Although endothelin receptor antagonists alleviate vasoconstriction, they incompletely address the remodeling process. We previously reported how endothelial-derived activin A promotes vascular remodeling, leading to the clinical development of the activin signaling inhibitor sotatercept, which improves outcomes when added to endothelin receptor antagonists. As both activin A and ET-1 originate from endothelial cells and promote remodeling, we investigated whether activin A regulates ET-1 production and activity in pulmonary arterial hypertension. METHODS: In vitro, we used pulmonary artery endothelial cell models of activin A overabundance alone or cocultured with pulmonary artery smooth muscle cells. Cells were treated with either the activin A inhibitor FST (follistatin), the endothelin receptor antagonist bosentan, the FST/bosentan combination, or vehicle for analysis. In vivo, we exposed wild-type or endothelial-specific INHBA (inhibin β-A)-overexpressing mice (VEcadherin-INHBA-Transgenic/VEcad-INHBA-Tg) to chronic hypoxia pulmonary hypertension model, with the addition of FST, bosentan, FST and bosentan, or vehicle treatments after the first week of hypoxia exposure. RESULTS: Activin A upregulated ET-1 expression via canonical SMAD2/3 (small mother against decapentaplegic family member 2/3) signaling in pulmonary artery endothelial cells. This induction, as well as ET-1–driven downstream effects—including reduced eNOS (endothelial NO synthase), pulmonary artery smooth muscle cell phenotypic switching, oxidative stress, and endothelial-to-mesenchymal transition—was reversed by FST alone or in combination with bosentan. In vivo, FST-based therapy achieved greater hemodynamic, right ventricular remodeling, and vascular structural normalization in wild-type and VEcad-INHBA-Tg mice than bosentan alone, accompanied by stronger ET-1 suppression. CONCLUSIONS: We identified ET-1 as a downstream effector of activin A in pulmonary arterial hypertension development, supporting activin A blockade as a strategy to inhibit ET-1–mediated vasoconstriction and remodeling. This mechanistic link provides a rationale for the rapid clinical benefits observed with sotatercept and suggests its potential role earlier in the pulmonary arterial hypertension treatment paradigm.
- 1 March 2021
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 41 (3) , 1076-1091
Chondroitin Sulfate N -acetylgalactosaminyltransferase-2 Impacts Foam Cell Formation and Atherosclerosis by Altering Macrophage Glycosaminoglycan Chain
Objective: Chondroitin sulfate proteoglycans are the primary constituents of the macrophage glycosaminoglycan and extracellular microenvironment. To examine their potential role in atherogenesis, we investigated the biological importance of one of the chondroitin sulfate glycosaminoglycan biosynthesis gene, ChGn-2 (chondroitin sulfate N -acetylgalactosaminyltransferase-2), in macrophage foam cell formation. Approach and Results: ChGn-2-deficient mice showed decreased and shortened glycosaminoglycans. ChGn-2 −/− /LDLr −/− (low-density lipoprotein receptor) mice generated less atherosclerotic plaque after being fed with Western diet despite exhibiting a metabolic phenotype similar to that of the ChGn-2 +/+ /LDLr −/− littermates. We demonstrated that in macrophages, ChGn-2 expression was upregulated in the presence of oxLDL (oxidized LDL), and glycosaminoglycan was substantially increased. Foam cell formation was significantly altered by ChGn-2 in both mouse peritoneal macrophages and the RAW264.7 macrophage cell line. Mechanistically, ChGn-2 enhanced oxLDL binding on the cell surface, and as a consequence, CD36—an important macrophage membrane scavenger receptor—was differentially regulated. Conclusions: ChGn-2 alteration on macrophages conceivably influences LDL accumulation and subsequently accelerates plaque formation. These results collectively suggest that ChGn-2 is a novel therapeutic target amenable to clinical translation in the future. Graphic A graphic abstract is available for this article.
- 1 March 2021
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 41 (3) , 1076-1091
Chondroitin Sulfate N -acetylgalactosaminyltransferase-2 Impacts Foam Cell Formation and Atherosclerosis by Altering Macrophage Glycosaminoglycan Chain
Objective: Chondroitin sulfate proteoglycans are the primary constituents of the macrophage glycosaminoglycan and extracellular microenvironment. To examine their potential role in atherogenesis, we investigated the biological importance of one of the chondroitin sulfate glycosaminoglycan biosynthesis gene, ChGn-2 (chondroitin sulfate N -acetylgalactosaminyltransferase-2), in macrophage foam cell formation. Approach and Results: ChGn-2-deficient mice showed decreased and shortened glycosaminoglycans. ChGn-2 −/− /LDLr −/− (low-density lipoprotein receptor) mice generated less atherosclerotic plaque after being fed with Western diet despite exhibiting a metabolic phenotype similar to that of the ChGn-2 +/+ /LDLr −/− littermates. We demonstrated that in macrophages, ChGn-2 expression was upregulated in the presence of oxLDL (oxidized LDL), and glycosaminoglycan was substantially increased. Foam cell formation was significantly altered by ChGn-2 in both mouse peritoneal macrophages and the RAW264.7 macrophage cell line. Mechanistically, ChGn-2 enhanced oxLDL binding on the cell surface, and as a consequence, CD36—an important macrophage membrane scavenger receptor—was differentially regulated. Conclusions: ChGn-2 alteration on macrophages conceivably influences LDL accumulation and subsequently accelerates plaque formation. These results collectively suggest that ChGn-2 is a novel therapeutic target amenable to clinical translation in the future. Graphic A graphic abstract is available for this article.